Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 105-110 , Summer 2009

Recent Advances in Mesothelioma Staging

  • William G. Richards, PhD

      Affiliations

    • Corresponding Author InformationAddress reprint requests to William G. Richards, PhD, Division of Thoracic Surgery, Harvard Medical School, Brigham and Women's Hospital, BWH Tissue and Blood Repository, 75 Francis Street, Boston, MA 02115

References 

  1. Feinstein AR. A new staging system for cancer and reappraisal of “early” treatment and “cure” by radical surgery. N Engl J Med. 1968;279:747–753
  2. Sellers AH. The clinical classification of malignant tumours: The TNM system. CMAJ. 1971;105:836
  3. Copeland MM. American Joint Committee on cancer staging and end results reporting (Objectives and progress). Cancer. 1965;18:1637–1640
  4. Butchart EG, Ashcroft T, Barnsley WC, et al. Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura (Experience with 29 patients). Thorax. 1976;31:15–24
  5. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: A retrospective study of 332 patients. J Clin Oncol. 1989;7:1157–1168
  6. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: Prognostic variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women's Hospital experience over two decades, 1965-85. J Clin Oncol. 1988;6:147–153
  7. Curran D, Sahmoud T, Therasse P, et al. Prognostic factors in patients with pleural mesothelioma: The European Organization for Research and Treatment of Cancer experience. J Clin Oncol. 1998;16:145–152
  8. Sugarbaker DJ, Strauss GM, Lynch TJ, et al. Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol. 1993;11:1172–1178
  9. Boutin C, Rey F, Gouvernet J, et al. Thoracoscopy in pleural malignant mesothelioma: A prospective study of 188 consecutive patients (Part 2: Prognosis and staging). Cancer. 1993;72:394–404
  10. Mattson K. Natural history and clinical stage of malignant mesothelioma. Eur J Respir Dis. 1982;63:87
  11. Dimitrov NV, McMahon S. Presentation, diagnostic methods, staging, and natural history of malignant mesothelioma. In:  Antman KH,  Aisner J editor. Asbestos-Related Disease. Orlando, FL: Grune & Stratton; 1987;p. 225–238
  12. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma (Results in 120 consecutive patients). Ann Surg. 1996;224:288–294
  13. Sugarbaker DJ, Flores RM, Jaklitsch MT, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J Thorac Cardiovasc Surg. 1999;117:54–63, discussion, 63-65
  14. Mineo TC, Ambrogi V, Pompeo E, et al. The value of occult disease in resection margin and lymph node after extrapleural pneumonectomy for malignant mesothelioma. Ann Thorac Surg. 2008;85:1740–1746
  15. Antman C, Blum RH, Greenberger JS, et al. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med. 1980;68:356–362
  16. Okiemy G, Foucault C, Avisse C, et al. Lymphatic drainage of the diaphragmatic pleura to the peritracheobronchial lymph nodes. Surg Radiol Anat. 2003;25:32–35
  17. Chahinian AP. Therapeutic modalities in malignant pleural mesothelioma. In:  Chretien J,  Hirsch A editor. Diseases of the Pleura. New York, NY: Masson; 1983;p. 224–236
  18. International Union Against Cancer (UICC). TNM atlas. In:  Speissel B,  Beahrs OH,  Hermanek P, et al. editor. Berlin: Springer; 1992;
  19. AJCC. Manual for Staging of Cancer. In:  Beahrs OH,  Hensen DE,  Hutter RVP, et al. editor. Philadelphia, PA: JB Lippincott; 1992;
  20. Tammilehto L, Kivisaari L, Salminen US, et al. Evaluation of the clinical TNM staging system for malignant pleural mesothelioma: An assessment in 88 patients. Lung Cancer. 1995;12:25–34
  21. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma (From The International Mesothelioma Interest Group). Chest. 1995;108:1122–1128
  22. Rusch V, Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 1996;111:815–826
  23. Flores RM, Zakowski M, Venkatraman E, et al. Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center. J Thorac Oncol. 2007;2:957–965
  24. UICC, International Union Against Cancer. TNM Classification of Malignant Disease. New York, NY: Wiley-Liss; 2002;
  25. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Manual. New York, NY: Springer; 2002;
  26. Flores RM, Routledge T, Seshan VE, et al. The impact of lymph node station on survival in 348 patients with surgically resected malignant pleural mesothelioma: Implications for revision of the American Joint Committee on Cancer staging system. J Thorac Cardiovasc Surg. 2008;136:605–610
  27. Flores RM, Akhurst T, Gonen M, et al. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg. 2003;126:11–16
  28. Richards WG, Godleski JJ, Yeap BY, et al. Proposed adjustments to pathologic staging of epithelial malignant pleural mesothelioma based on analysis of 354 cases. Cancer. 2009;in press

PII: S1043-0679(09)00077-X

doi: 10.1053/j.semtcvs.2009.07.002

Seminars in Thoracic and Cardiovascular Surgery
Volume 21, Issue 2 , Pages 105-110 , Summer 2009

Article Tools

* Image Usage & Resolution